Investigators found that some patients with high-risk nonmetastatic hormone-sensitive prostate cancer were understaged by ...

Telix Pharmaceuticals Limited today announces that the United States Food and Drug Administration has approved its New Drug ...

Telix’s Illuccix prostate cancer PSMA-PET imaging agent approved in the Netherlands: Melbourne, Australia Wednesday, March 19, 2025, 12:00 Hrs [IST] Telix, a biopharmaceutical c ...

PSMA PET/CT trial will scan up to 1000 men in the UKA new kind of scan that could be key to improving the treatment of high-risk prostate cancer is ...

One-third of patients with PSA levels below 0.2 ng/mL after radical prostatectomy have recurrent disease identifiable by PSMA PET. More than one-third of patients with PSA levels less than 0.5 ng ...

Joseph Renzulli, MD, Associate Professor of Urology at Yale School of Medicine, discusses how the scope of the utilization of PET scans has expanded based on the success of PSMA. (1:33 ...

Jacob E. Berchuck, MD, highlights challenges in adopting liquid biopsy for PSMA expression and its potential to revolutionize precision medicine in prostate cancer.

Brazilian Health Regulatory Agency (ANVISA) has granted approval for Telix Pharmaceuticals’ Illuccix, a prostate cancer imaging agent. Illuccix claims to be the first prostate-specific membrane ...

PSMA-PET imaging represents a significant advancement in prostate cancer management, providing clinicians with more information than conventional imaging methods (bone scan, CT [4] scan ...

Illuccix claims to be the first prostate-specific membrane antigen-positron emission tomography (PSMA-PET ... for PET imaging in conjunction with computerised tomography (CT) scan for identifying ...